Detalhe da pesquisa
1.
Two-Part Phase 1 Multiple-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of TRV734 in Healthy Adults.
Clin Pharmacol Drug Dev
; 11(1): 51-62, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480428
2.
A Phase I, Randomized, SingleBlind, PlaceboControlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects.
CNS Drugs
; 34(8): 853-865, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32676977
3.
A First-in-Human Clinical Study With TRV734, an Orally Bioavailable G-Protein-Biased Ligand at the µ-Opioid Receptor.
Clin Pharmacol Drug Dev
; 9(2): 256-266, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31286645
4.
Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors.
J Med Chem
; 49(5): 1597-612, 2006 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-16509577
5.
Novel bone antiresorptive approaches.
Curr Opin Pharmacol
; 2(3): 330-7, 2002 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12020479
6.
Biased agonism of the µ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers.
Pain
; 155(9): 1829-1835, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24954166
7.
A novel EPO receptor agonist improves glucose tolerance via glucose uptake in skeletal muscle in a mouse model of diabetes.
Exp Diabetes Res
; 2011: 910159, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21754921
8.
Mechanical injury potentiates proteoglycan catabolism induced by interleukin-6 with soluble interleukin-6 receptor and tumor necrosis factor alpha in immature bovine and adult human articular cartilage.
Arthritis Rheum
; 60(10): 2985-96, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19790045
9.
Proteoglycan degradation after injurious compression of bovine and human articular cartilage in vitro: interaction with exogenous cytokines.
Arthritis Rheum
; 48(5): 1292-301, 2003 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12746902
10.
Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.
Bioorg Med Chem Lett
; 13(8): 1483-6, 2003 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-12668017
11.
An azepanone-based inhibitor of human cathepsin K with improved oral bioavailability in the rat and the monkey.
Mol Pharm
; 1(1): 97-100, 2004 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-15832505